Protagonist Therapeutics (NASDAQ:PTGX) Director Sells $1,061,460.00 in Stock

Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Director William Waddill sold 9,000 shares of the firm’s stock in a transaction dated Tuesday, June 23rd. The stock was sold at an average price of $117.94, for a total value of $1,061,460.00. Following the transaction, the director owned 7,825 shares in the company, valued at approximately $922,880.50. This trade represents a 53.49% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Protagonist Therapeutics Price Performance

Shares of PTGX stock opened at $121.88 on Friday. The stock has a market cap of $7.84 billion, a PE ratio of -67.34 and a beta of 1.85. The stock has a 50-day moving average of $104.39 and a 200-day moving average of $95.18. Protagonist Therapeutics, Inc. has a one year low of $49.38 and a one year high of $126.25.

Protagonist Therapeutics (NASDAQ:PTGX) last released its quarterly earnings data on Tuesday, May 5th. The company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.50) by $0.55. The business had revenue of $56.37 million for the quarter, compared to analyst estimates of $11.70 million. Protagonist Therapeutics had a negative net margin of 154.88% and a negative return on equity of 17.76%. As a group, research analysts anticipate that Protagonist Therapeutics, Inc. will post 2.93 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on the company. Citizens Jmp increased their target price on Protagonist Therapeutics from $120.00 to $137.00 and gave the stock a “market outperform” rating in a research note on Wednesday, May 6th. Wolfe Research began coverage on shares of Protagonist Therapeutics in a research report on Thursday, May 21st. They set an “outperform” rating and a $135.00 price objective for the company. Johnson Rice restated a “buy” rating on shares of Protagonist Therapeutics in a report on Wednesday, March 18th. The Goldman Sachs Group restated a “neutral” rating and set a $110.00 price objective on shares of Protagonist Therapeutics in a report on Wednesday, May 6th. Finally, Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Protagonist Therapeutics in a research report on Friday, May 15th. One analyst has rated the stock with a Strong Buy rating, thirteen have issued a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $115.21.

Institutional Trading of Protagonist Therapeutics

A number of institutional investors have recently made changes to their positions in PTGX. Farther Finance Advisors LLC boosted its position in Protagonist Therapeutics by 110.6% during the fourth quarter. Farther Finance Advisors LLC now owns 297 shares of the company’s stock worth $26,000 after purchasing an additional 156 shares during the period. Oregon Public Employees Retirement Fund raised its position in shares of Protagonist Therapeutics by 1.5% in the fourth quarter. Oregon Public Employees Retirement Fund now owns 13,393 shares of the company’s stock valued at $1,170,000 after purchasing an additional 193 shares during the period. Maryland State Retirement & Pension System lifted its stake in shares of Protagonist Therapeutics by 2.3% during the 4th quarter. Maryland State Retirement & Pension System now owns 8,603 shares of the company’s stock worth $751,000 after buying an additional 196 shares during the last quarter. Sumitomo Mitsui Trust Group Inc. lifted its stake in shares of Protagonist Therapeutics by 7.8% during the 1st quarter. Sumitomo Mitsui Trust Group Inc. now owns 2,760 shares of the company’s stock worth $291,000 after buying an additional 200 shares during the last quarter. Finally, PNC Financial Services Group Inc. boosted its holdings in shares of Protagonist Therapeutics by 8.1% during the 4th quarter. PNC Financial Services Group Inc. now owns 2,959 shares of the company’s stock worth $258,000 after buying an additional 221 shares during the period. Institutional investors own 98.63% of the company’s stock.

Protagonist Therapeutics Company Profile

Protagonist Therapeutics, Inc (NASDAQ: PTGX) is a clinical-stage biopharmaceutical company focused on the development of novel, orally administered peptide-based therapies for immune-mediated and other serious diseases. The company leverages its proprietary Peptide 2.0 platform to design peptides that target G protein–coupled receptors and cytokine receptors, with the goal of combining the potency of biologics with the convenience of oral administration. Protagonist’s approach aims to address unmet medical needs in areas where injectable therapies have been the standard of care.

Among its lead programs is PTG-100, an oral α4β7 integrin antagonist intended to block leukocyte migration to the gut in ulcerative colitis and Crohn’s disease.